Literature DB >> 26838962

Extended criteria donors in liver transplantation Part I: reviewing the impact of determining factors.

Balázs Nemes1, György Gámán2, Wojciech G Polak3, Fanni Gelley4, Takanobu Hara5, Shinichiro Ono5, Zhassulan Baimakhanov5, Laszlo Piros2, Susumu Eguchi5.   

Abstract

The definition and factors of extended criteria donors have already been set; however, details of the various opinions still differ in many respects. In this review, we summarize the impact of these factors and their clinical relevance. Elderly livers must not be allocated for hepatitis C virus (HCV) positives, or patients with acute liver failure. In cases of markedly increased serum transaminases, donor hemodynamics is an essential consideration. A prolonged hypotension of the donor does not always lead to an increase in post-transplantation graft loss if post-OLT care is proper. Hypernatremia of less than 160 mEq/L is not an absolute contraindication to accept a liver graft per se. The presence of steatosis is an independent and determinant risk factor for the outcome. The gold standard of the diagnosis is the biopsy. This is recommended in all doubtful cases. The use of HCV+ grafts for HCV+ recipients is comparable in outcome. The leading risk factor for HCV recurrence is the actual RNA positivity of the donor. The presence of a proper anti-HBs level seems to protect from de novo HBV infection. A favourable outcome can be expected if a donation after cardiac death liver is transplanted in a favourable condition, meaning, a warm ischemia time < 30 minutes, cold ischemia time < 8-10 hours, and donor age 50-60 years. The pathway of organ quality assessment is to obtain the most relevant information (e.g. biopsy), consider the co-existing donor risk factors and the reserve capacity of the recipient, and avoid further technical issues.

Entities:  

Keywords:  HCV; Liver transplantation; biliary complications; donor; extended criteria; hepatitis C; machine perfusion; recurrence; steatosis

Mesh:

Year:  2016        PMID: 26838962     DOI: 10.1586/17474124.2016.1149061

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  12 in total

Review 1.  Machine perfusion strategies in liver transplantation.

Authors:  Andrea Schlegel; Xavier Muller; Philipp Dutkowski
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

2.  Postreperfusion Liver Biopsy as Predictor of Early Graft Dysfunction and Survival After Orthotopic Liver Transplantation.

Authors:  Esteban Fuentes-Valenzuela; Javier Tejedor-Tejada; Félix García-Pajares; Beatriz M Rubiales; Rodrigo Nájera-Muñoz; Carlos Maroto-Martín; Laura Sánchez-Delgado; Carmen Alonso-Martín; Carolina A Álvarez; Gloria Sánchez-Antolín
Journal:  J Clin Exp Hepatol       Date:  2022-01-04

3.  A Small Animal Model of Ex Vivo Normothermic Liver Perfusion.

Authors:  Eliza W Beal; Curtis Dumond; Jung-Lye Kim; Clifford Akateh; Emre Eren; Katelyn Maynard; Chandan K Sen; Jay L Zweier; Kenneth Washburn; Bryan A Whitson; Sylvester M Black
Journal:  J Vis Exp       Date:  2018-06-27       Impact factor: 1.355

Review 4.  Elderly donor graft for liver transplantation: Never too late.

Authors:  Harleen Chela; Mohamad H Yousef; Abdelmajeed A Albarrak; Bhupinder S Romana; Dania N Hudhud; Veysel Tahan
Journal:  World J Transplant       Date:  2017-12-24

5.  A novel hypothermic machine perfusion system using a LifePort Kidney Transporter for the preservation of rat liver.

Authors:  Cheng Zeng; Xiaoyan Hu; Yanfeng Wang; Xianpeng Zeng; Yan Xiong; Ling Li; Qifa Ye
Journal:  Exp Ther Med       Date:  2017-12-01       Impact factor: 2.447

Review 6.  Hypothermic Machine Preservation of the Liver: State of the Art.

Authors:  Andrea Schlegel; Xavier Muller; Philipp Dutkowski
Journal:  Curr Transplant Rep       Date:  2018-01-22

Review 7.  Impact of Machine Perfusion on Biliary Complications after Liver Transplantation.

Authors:  Andrea Schlegel; Philipp Dutkowski
Journal:  Int J Mol Sci       Date:  2018-11-12       Impact factor: 5.923

8.  The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation.

Authors:  Georg P Györi; David Pereyra; Benedikt Rumpf; Hubert Hackl; Christoph Köditz; Gregor Ortmayr; Thomas Reiberger; Michael Trauner; Gabriela A Berlakovich; Patrick Starlinger
Journal:  Hepatology       Date:  2020-04-23       Impact factor: 17.425

Review 9.  Liver grafts from hepatitis B surface antigen-positive donors: A review of the literature.

Authors:  Elisabetta Loggi; Fabio Conti; Alessandro Cucchetti; Giorgio Ercolani; Antonio Daniele Pinna; Pietro Andreone
Journal:  World J Gastroenterol       Date:  2016-09-21       Impact factor: 5.742

10.  Selected liver grafts from donation after circulatory death can be safely used for retransplantation - a multicenter retrospective study.

Authors:  Marjolein van Reeven; Otto B van Leeuwen; Danny van der Helm; Sarwa Darwish Murad; Aad P van den Berg; Bart van Hoek; Ian P J Alwayn; Wojciech G Polak; Robert J Porte
Journal:  Transpl Int       Date:  2020-03-09       Impact factor: 3.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.